歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Angiogenesis > BIBX 1382

瀏覽歷史

S80514

BIBX 1382

源葉(MedMol) 96%
  • 英文名:
  • BIBX 1382
  • 別名:
  • CAS號:
  • 196612-93-8
  • 分子式:
  • C18H19ClFN7
  • 分子量:
  • 387.8418
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S80514-5mg 96% ¥535.50元 6 - - - EA 加入購物車
源葉(MedMol) S80514-10mg 96% ¥1020.00元 7 - - - EA 加入購物車
源葉(MedMol) S80514-25mg 96% ¥1980.00元 6 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity
  • 靶點: EGFR:3 nM (IC50);ErbB2:3.4 μM (IC50);EGFR
  • 體外研究:
    Falnidamol (BIBX 1382) demonstrates antiproliferative activity in mitogenic assays performed with KB cells
  • 體內(nèi)研究:
    Falnidamol (BIBX 1382; p.o.; 10 mg/kg/day; 16 days) completely suppressed tumor growth of human A431 xenografts with respective a T/C value of 15% after 2 weeks of treatment. Falnidamol (50 mg/kg/day for 2 weeks) results in dephosphorylation of the EGF receptor in A431 xenograft-bearing mice. With Falnidamol (p.o.; 10 mg/kg/day; 16 days), the C4h is 2222 nM and the C24h is 244 nM. Animal Model: Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431, FaDu, or HN5 cells Dosage: 10 mg/kg Administration: p.o.; daily; 16 days Result: Completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment. Animal Model: Five- to six-week-old athymic NMRI-nu/nu female mice (21–31 g) with A431 cells Dosage: 10 mg/kg (Pharmacokinetic Analysis) Administration: p.o.; daily; 16 days Result: The C4h is 2222 nM and the C24h is 244 nM.
  • 參考文獻:
    1. Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. 2. Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.578 ml 12.892 ml 25.784 ml
    5 mM 0.516 ml 2.578 ml 5.157 ml
    10 mM 0.258 ml 1.289 ml 2.578 ml
    50 mM 0.052 ml 0.258 ml 0.516 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。